About US$1 billion, a size that would make it the largest IPO ever by an Indian hospital operator, is being prepared by Manipal Health Enterprises. The plan would likely combine a fresh share issue with an offer-for-sale to give private-equity backers and promoter shareholders a partial exit while raising new capital. One report names a fresh issue of Rs 8,000 crore and an offer-for-sale of up to 43.23 million shares, with proceeds earmarked to repay debt and to buy a stake in Sahyadri Hospitals. Draft papers were reported around January 2026, and a typical three- to four-month regulatory review could push a listing toward mid-2026 if market conditions permit.

Multiple accounts say Manipal Health Enterprises is lining up an offering of about US$1 billion that would combine new shares and an offer-for-sale. That structure has become commonplace for large Indian listings because it raises fresh capital while giving early investors a degree of liquidity, and it would also allow Manipal's private-equity backers and promoter shareholders to reduce holdings.

Deal size and use of proceeds

One report, Moneycontrol, provided the most granular picture. It said the fresh issue would amount to Rs 8,000 crore and the offer-for-sale could reach 43.23 million shares. Moneycontrol named planned sellers including Imperius Healthcare Investments, Manipal Education and Medical Group, TPG SG Magazine and Seventy Second Investment.

Those draft papers, according to the same report, set out specific uses for the proceeds. The fresh issuance would fund repayment of Rs 5,378 crore of debt and finance the acquisition of a minority stake in Sahyadri Hospitals for Rs 574 crore. The draft filing also listed consolidated outstanding borrowings of Rs 10,612.79 crore as of January 31, 2026.

Other reports, which don't attach the same line-by-line breakdown, nonetheless agree on the broad shape: a roughly US$1 billion headline size, split between primary capital and secondary sales. This combination aims to reduce leverage on the balance sheet while giving the company firepower for expansion and consolidation in a fragmented hospital market.

Advisers, scale and valuation

Several accounts name Kotak Mahindra Capital, Axis Bank or Axis Capital, Goldman Sachs, JPMorgan and Jefferies among the lead managers. One report also listed UBS and DBS as involved, and legal counsel teams were named for the company and for sellers in at least one account.

Mastheads

That mix of domestic and international banks is typical for a large Indian IPO, where lead managers handle regulatory filing, marketing and allocations to domestic and institutional investors.

The company’s scale underpins the valuation debates. Reports converge on a footprint of more than 10,500 to 10,761 licensed or operational beds across a network of more than 38 hospitals on a consolidated or pro forma basis in multiple states. Coverage repeatedly cites the group’s acquisition of Sahyadri Hospitals and prior capital raises as drivers of its expansion. One cited commitment from KKR of about $600 million was referenced by several accounts as having accelerated Manipal’s growth plans.

Published valuation estimates cluster but aren't identical. Some sources say the company could be valued at up to roughly US$13 billion.

Another account put a band of US$12-15 billion. Insiders quoted in those pieces said the final valuation would be decided nearer the offer and would depend on market appetite.

Comparisons in the reporting place a successful Manipal listing ahead of listed peers such as Max Healthcare and Apollo Hospitals on market-cap metrics cited in the pieces. That would mark a notable reshuffle among India’s hospital operators, and explains why the deal has attracted major domestic and global banks.

There are, however, contradictions in the coverage about timing and filing status. Moneycontrol reported that draft papers were filed with the securities regulator. Other outlets, by contrast, said Manipal planned to file draft documents in January 2026. Those accounts noted a typical three- to four-month regulatory review period, which would point to a potential mid-2026 listing if approvals and market conditions align. One source suggested a launch by the end of 2026 as an alternative timetable, subject to market conditions.

Market reception will be crucial. The promoter group and private-equity sellers must weigh price, timing and Balancing fresh capital and exits. The banks on the deal will similarly judge institutional demand and retail interest when setting the final size and price range.

For investors, the package combines scale, a clearer deleveraging intent and a route for early backers to monetise. For the company, the IPO would provide capital to pay down sizeable debt and to fund strategic acquisitions such as the Sahyadri stake noted in the draft documents.

Related Articles

Draft papers were reported or expected in January 2026, and a standard three- to four-month regulatory review would point to a potential listing by mid-2026, subject to market appetite and timing decisions by the company and its advisers.

This article was created with AI assistance.